Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

inhibitor designed to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new ...

Excessive screen time and chronic stress, especially in young people, disrupt circadian rhythms and immune function, ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...